Crinetics Pharmaceuticals (CRNX) Research & Development (2017 - 2026)

Crinetics Pharmaceuticals' Research & Development history runs 10 years deep, the most recent figure standing at $100.1 million for Q1 2026.

• On a quarterly basis, Research & Development rose 31.27% year-over-year to $100.1 million in Q1 2026; TTM through Mar 2026 was $301.8 million, a 14.73% increase from a year earlier, with the FY2025 full-year figure at $332.1 million, up 38.27% from the prior year.
• Research & Development advanced to $100.1 million in Q1 2026 per CRNX's latest filing, from $85.1 million in the prior quarter.
• Across five years, Research & Development topped out at $100.1 million in Q1 2026 and bottomed at -$61.6 million in Q4 2022.
• The 5-year median for Research & Development is $45.6 million (2023), against an average of $48.1 million.
• Across the five-year window, Research & Development plunged 350.25% in 2022 and jumped 174.03% in 2023, its largest moves.
• Year by year, Research & Development stood at -$61.6 million in 2022, then soared by 174.03% to $45.6 million in 2023, then soared by 46.04% to $66.6 million in 2024, then rose by 27.77% to $85.1 million in 2025, then climbed by 17.67% to $100.1 million in 2026.
• Per Business Quant, the three latest CRNX Research & Development figures stand at $100.1 million (Q1 2026), $85.1 million (Q4 2025), and $90.5 million (Q3 2025).